Aravax is a clinical stage biotechnology company dedicated to revolutionising the treatment of food allergy by developing next-generation, disease-modifying peptide-based immunotherapies that are safer and more convenient than existing approaches. Its lead programme is PVX108, in clinical development for the treatment of peanut allergy.
Looking for a particular Aravax employee's phone or email?
The Aravax annual revenue was $9 million in 2026.
Sara Prickett is the Chief Scientific Officer of Aravax.
6 people are employed at Aravax.
Aravax is based in Melbourne, Victoria.
The NAICS codes for Aravax are [54, 5417, 541, 541713, 54171].
The SIC codes for Aravax are [87, 873].